Tight Glycemic Control by Artificial Pancreas
Not Applicable
Completed
- Conditions
- Pancreatic Neoplasm
- Interventions
- Device: Artificial Pancreas (STG-22)
- Registration Number
- NCT00657995
- Lead Sponsor
- Kochi University
- Brief Summary
This study evaluated a closed-loop system providing continuous monitoring and strict control of perioperative blood glucose following pancreatic resection.
- Detailed Description
This study recruited 32 patients undergoing elective pancreatic resection for pancreatic disease.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
- This study recruited 32 patients undergoing elective pancreatic resection for pancreatic disease.
Exclusion Criteria
- weight loss greater than 10% during the previous 6 months
- signs of distant metastasis
- respiratory, renal,or heart disease
- Patients provided written informed consent prior to enrollment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 2 Artificial Pancreas (STG-22) Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.
- Primary Outcome Measures
Name Time Method the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas the first postoperative 18 hours in the surgical intensive care unit
- Secondary Outcome Measures
Name Time Method the total amount of insulin required for glycemic control after pancreatic resection the first postoperative 18 hours in the surgical intensive care unit
Trial Locations
- Locations (1)
Kochi Medical School, Kochi University
🇯🇵Nankoku-City, Kohasu-Okocho, Japan